* Ratio is calculated based on latest financial & current share price.
(All Amount in INR Millions)
(All Amount in INR Millions)
(All Amount in INR Millions)
Veeda Clinical Research Limited is one of India’s largest and well-known Clinical Research Organisations (CRO). They specialise in providing clinical services to global pharma and biotech industries.
Veeda Clinical has served a variety of global clients including major pharma companies like Mankind Pharma, Dr Reddy Laboratories and Granules India. Their international clients include Laboritorios Licensa in Europe & Novugen Pharma in Malaysia.
Veeda Clinical has refiled its Draft Red Herring Prospectus (DRHP) in 2025. This planned IPO will have a face value of Rs 2 per share and combines a fresh issue of shares worth Rs 185 crore and an Offer for Sale for 13 Million Equity Shares by existing shareholders.
| Amount(In Rs Crores) | FY 21-22 | FY 22-23 | FY 23-24 |
| Revenue | 288 | 409 | 388 |
| EBITDA | 62 | 103 | 53 |
| Operating Profit Margin(%) | 21.53% | 25.18% | 13.66% |
| Profit After Tax | 50 | 42 | -0.3 |
| Earning Per Share | 9.46 | 8 | -0.4 |
A) Revenue Growth
Veeda Clinical’s revenue has grown from Rs 288 crores in FY 21-22 to Rs 409 crores in Fy 22-23. This dropped to Rs 388 crore in Fy 23-24 which is 26% growth in 2 years.
This reflects a growth in operations of Veeda Clinical Research Unlisted Shares.
B) EBITDA
Veeda Clinical’s EBITDA grew from Rs 62 crores in FY 21-22 to Rs 103 crores in FY23-24. But reduced to Rs 53 crores in Fy 23-24.
C) Profit Margin
Veeda’s Operating profit margin has decreased in the last 3 years. In Fy 22, the Operating Profit margin was 21.53%, In Fy 23, the OPM grew to 25% but reduced to 13. 66% in Fy 24.
This is still a decent profitability rate for Veeda Clinical Research unlisted shares.
D) Profit after Tax
Veeda Clinical’s PAT was Rs 50 cr. in Fy 22 which dropped to a loss of Rs 40 Lacs in FY 24.
Profit After Taxa is a significant contributing factor to the growth of Veeda Clinical Research Share Price.
E) Earnings Per Share
Veeda’s earnings per share was Rs 9.46 per share in FY 22. This reduced to Rs 8 per share in FY 23 and Rs -0.4 per share in FY 24.
Earnings per share and P/E Ratio affect the Veeda Clinical Research stock price.
Thus based on the above financial observations, Veeda Clinical Research Unlisted Shares can give significant investment growth to investors.
Buying and selling unlisted shares can be complex if you’re not aware of the process correctly. If you’re considering buying Veeda Clinical Research Unlisted Shares and need help with how to go about it, India’s best unlisted shares broking platforms are here to help.
There are many factors to consider before applying to unlisted shares, including EPS growth, KPI, EBITDA Margin, Profit & Loss summary, etc. The experts at Stockify will provide you with every valuable piece of information you need.
At Stockify, you get updated prices of Veeda Clinical Research Unlisted Shares, and the current Veeda Clinical Research Share Price Today is Rs. 525 per share. Keeping oneself updated with the costs of unlisted shares makes buying and selling easy. Since our experts possess a tremendous knowledge of the grey market, they update the prices whenever they get changed.
So log in and subscribe to our Finance Newsletter for regular stock updates.
Are you interested in buying unlisted shares of other companies apart from Veeda Clinical? If yes, Stockify brings you a vast list of leading companies offering unlisted shares for potential investors to earn something big. You can choose the company to invest in the stock from manufacturing to healthcare, education, and energy. The companies you will find on Stockify are the best unlisted shares in India to buy. Just scroll through our list and get the updates on any unlisted company you’re looking for. For more information, we’re always here; connect with us.
Reliance Retail, Pharmeasy, Chennai super kings, Anglo-French Drugs & Industries, Hexaware Technologies Ltd, Five Star Business Finance Ltd Unlisted Shares, Fincare Small Finance Bank Ltd Unlisted Shares, Arohan Financial Services Unlisted Shares, Utkarsh Coreinvest Ltd Unlisted Shares, Fino Paytech Ltd Unlisted Shares, Hero Fincorp Ltd Unlisted Shares, National Stock Exchange Ltd Nse Unlisted Shares, National Commodity Derivatives Exchange Ltd Ncdex Unlisted Shares, MetroPolitan Stock Exchange MSEI Unlisted Shares, Capital, Small Finance Bank Ltd Unlisted Shares, And Motilal Oswal Home Finance Ltd Unlisted Shares.
